Veracyte(VCYT) ZACKS·2025-03-13 13:45Core Viewpoint - Veracyte (VCYT) has demonstrated strong performance with a 45.6% increase in share price over the past year, significantly outperforming the industry and S&P 500, driven by the success of its Afirma and Decipher tests [1][3]. Company Overview - Veracyte, based in San Francisco, CA, specializes in advanced genomic tests that enhance diagnostic and treatment decisions for cancer and other diseases, aiming to reduce unnecessary procedures and expedite treatment [2]. Key Growth Catalysts - The growth in Veracyte's share price is attributed to the strong performance of Afirma and Decipher tests, with Afirma test volumes increasing by 12% in 2024 and 8% year-over-year in Q4, driven by deeper market penetration and new customer acquisition [3] - Decipher has been recognized in the updated 2025 NCCN guidelines as a leading gene expression test for personalized prostate cancer treatment, achieving a remarkable 45% year-over-year volume growth in Q4 [4] - Veracyte is expanding its testing capabilities to cover the entire prostate cancer risk spectrum, with plans to launch into this expanded market in the first half of 2025 [5]. Financial Estimates - The Zacks Consensus Estimate for Veracyte's 2025 earnings per share (EPS) is 486.2 million in 2025 and further growth to $533.7 million in 2026, an increase of 9.3% [9].